Hollings Home  
 
Graham W Warren, MD, PhD
Associate Professor of Radiation Oncology
College of Medicine
MUSC

Email: warrengw@musc.edu
 
       Print This Page
       
 
 


 

Graham W Warren, MD, PhD

Return to Search Page  

Research Interest:

I am a Board Certified radiation oncologist with a PhD in Toxicology, and my primary research interest is in evaluating the effects of tobacco and tobacco-related products on therapeutic response in cancer patients.  My research approach involves evaluation of how exposures alter tumor biology in preclinical basic laboratory systems, evaluating the epidemiology and health behaviors related to tobacco use and other exposures by cancer patients, the clinical effects of exposure to tobacco on therapeutic response as well as both cancer-related and non-cancer related health outcomes, evaluating the cost-based outcomes of tobacco and cessation on cancer treatment, and policy considerations for standard clinical practice and clinical trials design. 

Selected Publications:

1.Sobus SL, Warren GW. The biologic effects of cigarette smoke on cancer cells. Cancer. ., 2014.
View in: PubMed

2.Warren GW. Cigarette smoking and systemic therapy for lung cancer: considering the evidence to improve cancer care. J Thorac Oncol. .9(7):914-6, 2014.
View in: PubMed

3.Cummings KM, Dresler CM, Field JK, Fox J, Gritz ER, Hanna NH, Ikeda N, Jassem J, Mulshine JL, Peters MJ, Yamaguchi NH, Warren G, Zhou C. E-cigarettes and cancer patients. J Thorac Oncol. .9(4):438-41, 2014. PMCID: PMC4040965
View in: PubMed

4.Warren GW, Alberg AJ, Kraft AS, Cummings KM. The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. .120(13):1914-6, 2014.
View in: PubMed

5.Gritz ER, Toll BA, Warren GW. Tobacco use in the oncology setting: advancing clinical practice and research. Cancer Epidemiol Biomarkers Prev. .23(1):3-9, 2014. PMCID: PMC3893715
View in: PubMed

6.Balogh EP, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing tobacco-related cancer incidence and mortality: summary of an institute of medicine workshop. Oncologist. .19(1):21-31, 2013. PMCID: PMC3903060
View in: PubMed

7.Warren GW, Marshall JR, Cummings KM, Zevon MA, Reed R, Hysert P, Mahoney MC, Hyland AJ, Nwogu C, Demmy T, Dexter E, Kelly M, O'Connor RJ, Houstin T, Jenkins D, Germain P, Singh AK, Epstein J, Dobson Amato KA, Reid ME. Automated tobacco assessment and cessation support for cancer patients. Cancer. .120(4):562-9, 2013.
View in: PubMed

8.Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing tobacco use in patients with cancer: a survey of American Society of Clinical Oncology members. J Oncol Pract. .9(5):258-62, 2013. PMCID: PMC3770508
View in: PubMed

9.Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C. Practice patterns and perceptions of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thorac Oncol. .8(5):543-8, 2013. PMCID: PMC3628367
View in: PubMed

10.Warren GW, Singh AK. Nicotine and lung cancer. J Carcinog. .12:1, 2013. PMCID: PMC3622363
View in: PubMed

11.Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book. .359-64, 2013.
View in: PubMed

12.Fung SF, Warren GW, Singh AK. Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy, mediastinal lymphadenectomy, and novel systemic therapy. J Carcinog. .11:20, 2012. PMCID: PMC3548357
View in: PubMed

13.Malik NK, May KS, Chandrasekhar R, Wee W, Flaherty L, Iyer R, Gibbs J, Kuvshinoff B, Wilding G, Warren G, Yang GY. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. J Gastrointest Oncol. .3(4):326-34, 2012. PMCID: PMC3492478
View in: PubMed

14.Wells JL, Shirai K. Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients. Am J Clin Oncol. .35(5):498-503, 2012.
View in: PubMed

15.Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, Herbst RS, Marshall JR, Warren GW. Tobacco assessment in actively accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol. .30(23):2869-75, 2012. PMCID: PMC3410402
View in: PubMed

16.Schmitt JD, Warren GW, Wang IZ. Potential increase in biological effectiveness from field timing optimization for stereotactic body radiation therapy. Med Phys. .39(6):2956-63, 2012.
View in: PubMed

17.Platek ME, McCloskey SA, Cruz M, Burke MS, Reid ME, Wilding GE, Rigual NR, Popat SR, Loree TR, Gupta V, Warren GW, Sullivan M, Hicks WL, Singh AK. Quantification of the effect of treatment duration on local-regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. Head Neck. .35(5):684-8, 2012.
View in: PubMed

18.Warren GW, Kasza KA, Reid ME, Cummings KM, Marshall JR. Smoking at diagnosis and survival in cancer patients. Int J Cancer. .132(2):401-10, 2012.
View in: PubMed

19.Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, Rangnekar VM. Nicotinic modulation of therapeutic response in vitro and in vivo. Int J Cancer. .131(11):2519-27, 2012.
View in: PubMed

20.Warren GW, Arnold SM, Valentino JP, Gal TJ, Hyland AJ, Singh AK, Rangnekar VM, Cummings KM, Marshall JR, Kudrimoti MR. Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population. Radiother Oncol. .103(1):45-8, 2011. PMCID: PMC3327779
View in: PubMed

21.Martin KL, Gomez J, Nazareth DP, Warren GW, Singh AK. Quantification of incidental mediastinal and hilar irradiation delivered during definitive stereotactic body radiation therapy for peripheral non-small cell lung cancer. Med Dosim. .37(2):182-5, 2011.
View in: PubMed

22.Gosselin MH, Mahoney MC, Cummings KM, Loree TR, Sullivan M, King BA, Warren G, Hyland A. Evaluation of an intervention to enhance the delivery of smoking cessation services to patients with cancer. J Cancer Educ. .26(3):577-82, 2011.
View in: PubMed

23.Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. .17(18):6097-105, 2011. PMCID: PMC3176980
View in: PubMed

24.Kearney PL, Watkins JM, Shirai K, Wahlquist AE, Fortney JA, Garrett-Mayer E, Gillespie MB, Sharma AK. Salvage Resection for Isolated Local and/or Regional Failure of Head/Neck Cancer Following Definitive Concurrent Chemoradiotherapy Case Series and Review of the Literature. Mcgill J Med. .13(2):29, 2011. PMCID: PMC3277417
View in: PubMed

25.Platek ME, Merzianu M, Mashtare TL, Popat SR, Rigual NR, Warren GW, Singh AK. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol. .6:41, 2011. PMCID: PMC3098784
View in: PubMed

26.Shirai K, Kaneshiro T, Wada M, Furuya H, Bielawski J, Hannun YA, Obeid LM, Ogretmen B, Kawamori T. A role of sphingosine kinase 1 in head and neck carcinogenesis. Cancer Prev Res (Phila). .4(3):454-62, 2011. PMCID: PMC3342666
View in: PubMed

27.Platek ME, Reid ME, Wilding GE, Jaggernauth W, Rigual NR, Hicks WL, Popat SR, Warren GW, Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head Neck. ., 2010.
View in: PubMed

28.Platek ME, Reid ME, Wilding GE, Jaggernauth W, Rigual NR, Hicks WL, Popat SR, Warren GW, Sullivan M, Thorstad WL, Khan MK, Loree TR, Singh AK. Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head Neck. .33(11):1561-8, 2010.
View in: PubMed

29.Watkins JM, Zauls AJ, Kearney PL, Shirai K, Ruppert BN, Harper JL, Sherman CA, Aguero EG, Reed CE, Sharma AK. Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Jpn J Clin Oncol. .41(3):334-42, 2010.
View in: PubMed

30.Watkins JM, Wahlquist AE, Zauls AJ, Shirai K, Garrett-Mayer E, Aguero EG, Silvestri GA, Sherman CA, Sharma AK. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. .54(5):483-9, 2010.
View in: PubMed

31.Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol. .29(2):100-6, 2010.
View in: PubMed

32.Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Garrett-Mayer E, Aguero EG, Sherman CA, Reed CE, Sharma AK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. .33(4):346-52, 2010.
View in: PubMed

33.Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Sherman CA, Turrisi AT, Sharma AK. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol. .28(5):340-8, 2010.
View in: PubMed

34.Walters FS, deFontes CM, Hart H, Warren GW, Chen JS. Lepidopteran-active variable-region sequence imparts coleopteran activity in eCry3.1Ab, an engineered Bacillus thuringiensis hybrid insecticidal protein. Appl Environ Microbiol. .76(10):3082-8, 2010. PMCID: PMC2869115
View in: PubMed

35.Watkins JM, Zauls AJ, Wahlquist AH, Shirai K, Garrett-Mayer E, Gillespie MB, Day TA, Sharma AK. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. .120(2):236-42, 2010.
View in: PubMed

36.Shirai K, Sera Y, Bulkeley W, Mehrotra M, Moussa O, LaRue AC, Watson DK, Stuart RK, Lazarchick J, Ogawa M. Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemia. Exp Hematol. .37(12):1464-71, 2009. PMCID: PMC2802494
View in: PubMed

37.Watkins JM, Shirai KS, Wahlquist AE, Stuart RK, Chaudhary UB, Garrett-Mayer E, Day TA, Gillespie MB, Sharma AK. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. .31(4):493-502, 2009.
View in: PubMed

38.Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, Sherman CA, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. .74(4):1108-13, 2008.
View in: PubMed

39.Jucovic M, Walters FS, Warren GW, Palekar NV, Chen JS. From enzyme to zymogen: engineering Vip2, an ADP-ribosyltransferase from Bacillus cereus, for conditional toxicity. Protein Eng Des Sel. .21(10):631-8, 2008.
View in: PubMed

40.Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, St Clair WH. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther. .6(9):2477-86, 2007. PMCID: PMC2627774
View in: PubMed

41.Shirai K, O'Brien PE. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. .8(3):239-51, 2007.
View in: PubMed

42.Shirai K, Chaudhary UB. Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer--a case report. ScientificWorldJournal. .7:753-5, 2007.
View in: PubMed

43.Grimes KR, Warren GW, Fang F, Xu Y, St Clair WH. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep. .16(4):771-6, 2006.
View in: PubMed

44.Herrem CJ, Tatsumi T, Olson KS, Shirai K, Finke JH, Bukowski RM, Zhou M, Richmond AL, Derweesh I, Kinch MS, Storkus WJ. Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res. .11(1):226-31, 2005.
View in: PubMed

45.Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. .88(1):1-7, 1999.
View in: PubMed